Structural repurposing of SGLT2 inhibitor empagliflozin for strengthening anti-heart failure activity with lower glycosuria.
Xu Y, Zhang C, Jiang K, Yang X, Chen F, Cheng Z, Zhao J, Cheng J, Li X, Chen X, Zhou L, Duan H, Huang Y, Xiang Y, Li J.
Xu Y, et al. Among authors: huang y.
Acta Pharm Sin B. 2023 Apr;13(4):1671-1685. doi: 10.1016/j.apsb.2022.08.023. Epub 2022 Sep 5.
Acta Pharm Sin B. 2023.
PMID: 37139418
Free PMC article.